Another autologous vaccine discussed previously, Vigil, which educates T-cells to the relevant clonal tumor neoantigens and increases peripheral circulating CD3+/CD8+ T-cells in combination with ICIs is a logical next step. This evidence concerns the gene CD8A and neoplasm.